All In Biotech

NDA 213004 · Talicia Holdings

Talicia

Amoxicillin, Omeprazole Magnesium, Rifabutin · Oral · Rifamycin Antimycobacterial

Priority review

Last checked: Nov 20, 2026Latest source record: May 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 1, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

918

176 Phase 3, 89 recruiting

FAERS reports

219

30 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 23, 2025.

TALICIA is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial, indicated for the treatment of Helicobacter pylori infection in adults. ( 1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TALICIA and other antibacterial drugs, TALICIA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.2) 1.1 Helicobacter pylori Infection TALICIA is indicated for the treatment of Helicobacter pylori infection in adults [see Clinical Studies (14 ) ] . 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of TALICIA and other antibacterial drugs, TALICIA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: TALICIA is a combination of antibacterial drugs (rifabutin, amoxicillin) and a proton pump inhibitor (omeprazole as omeprazole magnesium), an antisecretory drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 1, 2019 Original approval · Type 4 - New Combination · priority review LabelLetterReview
1 products under this application
  • TALICIA · AMOXICILLIN 250MG; OMEPRAZOLE MAGNESIUM EQ 10MG BASE; RIFABUTIN 12.5MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.

All 918 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective32
  • rash25
  • treatment failure21
  • headache18
  • nausea18
  • diarrhoea16
  • fatigue16
  • pain11
  • vomiting11
  • abdominal pain10
  • dizziness10
  • pruritus9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202017
202156
202250
202352
202426
202516
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Talicia (Omeprazole/Amoxicill/Rifabutin)

2024 spending

$2.6M

Beneficiaries

3,265

3,346 claims

Per beneficiary

$802

$4.68 per unit

View as table
YearSpending
2020$760,190
2021$2,294,083
2022$3,111,790
2023$3,328,152
2024$2,619,687

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,171 on PubMed

Sponsor: Talicia Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.